Salvage therapy with brentuximab-vedotin and bendamustine for patients with R/R PTCL: a retrospective study from the LYSA.
Gandhi Laurent DamajRaphaelle AubraisKrimo BouabdallahLoic ChartierCharles HerbauxAnne BanosPauline BriceDavid SibonJean Marc Schiano De ColellaThomas CluzeauKamel LaribiRonan LE CallochMathieu BellalBaptiste DelapierreNicolas DaguindauSandy AmorimKossi AgbetiafaAdrien ChauchetCaroline BessonEric DurotChristophe BonnetLudovic FouilletFontanet BijouOlivier TournilhacPhilippe GaulardMarie-Cécile ParrensPublished in: Blood advances (2022)
BBv is highly active in patients with R/R PTCL and should be considered as a one of the best option of immunochemotherapy salvage combination in this setting and particularly as a bridge to allogeneic transplant for eligible patients.